Ayesha Azhar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Ayesha Azhar has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Muskan Asim Taimuri
Department of Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan
4 shared publications - Areeba Ikram
Department of Internal Medicine, Dow University of Health Sciences, Karachi, Pakistan
2 shared publications Asra Zainab
Dow University of Health Sciences, Karachi, Pakistan
2 shared publications- Aymar Akilimali
Faculty of Medicine University of Goma Goma DR Congo
2 shared publications - Malik Olatunde Oduoye
Department of Research The Medical Research Circle Goma Congo
2 shared publications - Shamat Fathi Shamat
Faculty of Medicine, National Ribat University, Khartoum, Sudan
2 shared publications
Latest Publications
- Open Access
- 30 August 2024
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 86 (10) , 5966-5972
Deep brain stimulation for post-stroke rehabilitation in Pakistan
Stroke has a high prevalence in Pakistan, at an alarming rate of 250 per 100 000 people. Although various treatment options are available, they are not ideal for Pakistan due to their high cost, restricted availability, and time sensitivity. In 1997, the FDA-approved deep brain stimulation (DBS) for Parkinson’s disease and it was first performed in Pakistan in 2014. DBS has also proved effective for restoring post-stroke mobility, according to a trial from August 2023. DBS has the potential to revolutionize post-stroke rehabilitation in Pakistan; however, further research is required into its effectiveness and its limitations must be addressed first.
- 30 August 2024
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 86 (10) , 5966-5972
Open AccessDeep brain stimulation for post-stroke rehabilitation in Pakistan
Stroke has a high prevalence in Pakistan, at an alarming rate of 250 per 100 000 people. Although various treatment options are available, they are not ideal for Pakistan due to their high cost, restricted availability, and time sensitivity. In 1997, the FDA-approved deep brain stimulation (DBS) for Parkinson’s disease and it was first performed in Pakistan in 2014. DBS has also proved effective for restoring post-stroke mobility, according to a trial from August 2023. DBS has the potential to revolutionize post-stroke rehabilitation in Pakistan; however, further research is required into its effectiveness and its limitations must be addressed first.
- Open Access
- 21 May 2024
- Published by Wiley in Health Science Reports
- Vol. 7 (5) , e2081
The influence of sociodemographic factors on parental health‐seeking behavior for illnesses among the pediatric age group in Karachi: A cross‐sectional study
Background: Health‐seeking behavior (HSB) is an individual's reaction to sickness, for which they seek medical attention, regardless of the form such care may take. Poor HSB is frequently associated with lower health outcomes and greater mortality and disease rates in a nation. Sociodemographic factors, including age, gender, family structure, occupation, ethnicity, and rates of literacy and poverty, can influence a person's HSB. This study would benefit Pakistani parents of the paediatric population to make more informed health choices for their children.Aim: This study aims to determine the influence of sociodemographic factors on parental HSB for illnesses among the pediatric age group in Karachi.Materials and Methods: A cross‐sectional study was conducted in which 214 parents were interviewed about their choices for health‐seeking healthcare for their pediatric children of the pediatric age group (birth–18 years), who were attending the pediatric OPD and wards at Dr. Ruth Pfau Civil Hospital, Karachi in May 2023. Only parents or guardians with sick children were included. Their sociodemographic characteristics and health‐seeking choices were asked. Informed consent was obtained, and all data were recorded. SPSS version 25 was used for analysis.Results: For the first choice, the majority of parents (82.7%) preferred to seek healthcare for their children from medical doctors, followed by spiritual healers (10.7%), traditional healers (5.6%), and homoeopathic doctors (0.9%). For the second choice, the highest percentage was for a doctor (76.2%), followed by a spiritual healer (18.7%), a homoeopathic doctor (3.3%), and a traditional healer (1.9%). A significant correlation was found between the first visit and the decision makers (p = 0.019), the father's education level of the father (p = 0.001), the mother's occupation of the mother (p = 0.019), and the mother's education level of the mother (p = 0.001).Conclusion: Sociodemographic characteristics greatly influence parents' HSBs of parents for their children. Despite having low‐paying jobs and being uneducated, most people choose to refer to a doctor for their child due to awareness.
- 21 May 2024
- Published by Wiley in Health Science Reports
- Vol. 7 (5) , e2081
Open AccessThe influence of sociodemographic factors on parental health‐seeking behavior for illnesses among the pediatric age group in Karachi: A cross‐sectional study
Background: Health‐seeking behavior (HSB) is an individual's reaction to sickness, for which they seek medical attention, regardless of the form such care may take. Poor HSB is frequently associated with lower health outcomes and greater mortality and disease rates in a nation. Sociodemographic factors, including age, gender, family structure, occupation, ethnicity, and rates of literacy and poverty, can influence a person's HSB. This study would benefit Pakistani parents of the paediatric population to make more informed health choices for their children.Aim: This study aims to determine the influence of sociodemographic factors on parental HSB for illnesses among the pediatric age group in Karachi.Materials and Methods: A cross‐sectional study was conducted in which 214 parents were interviewed about their choices for health‐seeking healthcare for their pediatric children of the pediatric age group (birth–18 years), who were attending the pediatric OPD and wards at Dr. Ruth Pfau Civil Hospital, Karachi in May 2023. Only parents or guardians with sick children were included. Their sociodemographic characteristics and health‐seeking choices were asked. Informed consent was obtained, and all data were recorded. SPSS version 25 was used for analysis.Results: For the first choice, the majority of parents (82.7%) preferred to seek healthcare for their children from medical doctors, followed by spiritual healers (10.7%), traditional healers (5.6%), and homoeopathic doctors (0.9%). For the second choice, the highest percentage was for a doctor (76.2%), followed by a spiritual healer (18.7%), a homoeopathic doctor (3.3%), and a traditional healer (1.9%). A significant correlation was found between the first visit and the decision makers (p = 0.019), the father's education level of the father (p = 0.001), the mother's occupation of the mother (p = 0.019), and the mother's education level of the mother (p = 0.001).Conclusion: Sociodemographic characteristics greatly influence parents' HSBs of parents for their children. Despite having low‐paying jobs and being uneducated, most people choose to refer to a doctor for their child due to awareness.
- Open Access
- 17 April 2024
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 86 (6) , 3530-3534
Ryzumvi: pioneering advances in countering drug-induced mydriasis
This article discusses the prevalence and impact of pharmacologically-induced mydriasis, a condition where the pupil becomes excessively dilated due to certain drugs. It highlights the challenges faced by medical professionals in dealing with this condition and the limitations of current treatments, like pilocarpine and dapiprazole, which come with systemic side effects and specific contraindications, limiting their regular use. The article introduces Ryzumvi, a novel ophthalmic solution approved by the US FDA, which effectively reverses mydriasis caused by adrenergic agonists and antimuscarinic drugs. The article provides insights into its mechanism of action, clinical efficacy, pharmacokinetics, safety, and tolerance based on extensive clinical trials. It emphasizes its rapid onset of action and effectiveness in restoring pupils to their initial size. It also underlines the potential for expanded applications, including in pediatric patients, solidifying its importance in the field of ophthalmology. Furthermore, Ryzumvi represents a promising advancement in managing pharmacologically-induced mydriasis, offering swift and effective relief while highlighting the importance of adhering to safety precautions and the continuous research and development efforts in ophthalmology to comprehensively address vision-related disorders and enhance patient outcomes.
- 17 April 2024
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 86 (6) , 3530-3534
Open AccessRyzumvi: pioneering advances in countering drug-induced mydriasis
This article discusses the prevalence and impact of pharmacologically-induced mydriasis, a condition where the pupil becomes excessively dilated due to certain drugs. It highlights the challenges faced by medical professionals in dealing with this condition and the limitations of current treatments, like pilocarpine and dapiprazole, which come with systemic side effects and specific contraindications, limiting their regular use. The article introduces Ryzumvi, a novel ophthalmic solution approved by the US FDA, which effectively reverses mydriasis caused by adrenergic agonists and antimuscarinic drugs. The article provides insights into its mechanism of action, clinical efficacy, pharmacokinetics, safety, and tolerance based on extensive clinical trials. It emphasizes its rapid onset of action and effectiveness in restoring pupils to their initial size. It also underlines the potential for expanded applications, including in pediatric patients, solidifying its importance in the field of ophthalmology. Furthermore, Ryzumvi represents a promising advancement in managing pharmacologically-induced mydriasis, offering swift and effective relief while highlighting the importance of adhering to safety precautions and the continuous research and development efforts in ophthalmology to comprehensively address vision-related disorders and enhance patient outcomes.
- Open Access
- 13 March 2024
- Published by SAGE Publications in Women's Health
- Vol. 20
Care for breast cancer survivors in Asian countries: A review of sexual dysfunction
Breast cancer accounts for one in three new cancer cases in women each year. Despite having a higher survival rate than other cancers, it is associated with various side effects, including anorgasmia, vaginismus, hair loss, and decreased libido. This review aims to explore trends in the incidence of sexual dysfunction in breast cancer survivors, the etiology of sexual dysfunction, and the role of factors such as family history, age, duration of marriage, and depression in predisposing patients. We summarize the limitations of the treatment modalities already used to cater to sexual dysfunction in breast cancer survivors and patients. The authors conducted searches on databases such as PubMed and Google Scholar using relevant search terms: sexual dysfunction, breast cancer, breast cancer survivors, chemotherapy, dyspareunia, vaginismus, and anorgasmia from 1997–2023. The inclusion criteria encompassed all types of articles with abstracts or titles indicating research on sexual dysfunction in breast cancer survivors in Asia. A total of 64 articles were included out of which 10 were systematic reviews and meta-analyses. The literature search yielded results showing high incidence rates of breast cancer in Asia (45.4%), with 31.6%–91.2% of breast cancer survivors likely to experience sexual dysfunction. Regional differences were noted, as female sexual dysfunction occurred in 74.1% of Asian breast cancer women. Further randomized controlled trials should be conducted to assess the effectiveness of treatment modalities. Personalized approaches should be tailored to address beliefs, such as the potential impact of sexual activity on disease recovery. Utilizing a family history of breast cancer as a preemptive tool can help reduce the risk of developing female sexual dysfunction in survivors, and factors such as age and depression should be considered when formulating solutions.
- 13 March 2024
- Published by SAGE Publications in Women's Health
- Vol. 20
Open AccessCare for breast cancer survivors in Asian countries: A review of sexual dysfunction
Breast cancer accounts for one in three new cancer cases in women each year. Despite having a higher survival rate than other cancers, it is associated with various side effects, including anorgasmia, vaginismus, hair loss, and decreased libido. This review aims to explore trends in the incidence of sexual dysfunction in breast cancer survivors, the etiology of sexual dysfunction, and the role of factors such as family history, age, duration of marriage, and depression in predisposing patients. We summarize the limitations of the treatment modalities already used to cater to sexual dysfunction in breast cancer survivors and patients. The authors conducted searches on databases such as PubMed and Google Scholar using relevant search terms: sexual dysfunction, breast cancer, breast cancer survivors, chemotherapy, dyspareunia, vaginismus, and anorgasmia from 1997–2023. The inclusion criteria encompassed all types of articles with abstracts or titles indicating research on sexual dysfunction in breast cancer survivors in Asia. A total of 64 articles were included out of which 10 were systematic reviews and meta-analyses. The literature search yielded results showing high incidence rates of breast cancer in Asia (45.4%), with 31.6%–91.2% of breast cancer survivors likely to experience sexual dysfunction. Regional differences were noted, as female sexual dysfunction occurred in 74.1% of Asian breast cancer women. Further randomized controlled trials should be conducted to assess the effectiveness of treatment modalities. Personalized approaches should be tailored to address beliefs, such as the potential impact of sexual activity on disease recovery. Utilizing a family history of breast cancer as a preemptive tool can help reduce the risk of developing female sexual dysfunction in survivors, and factors such as age and depression should be considered when formulating solutions.
- 7 October 2023
- Published by Springer Nature in European Archives of Oto-Rhino-Laryngology
- Vol. 281 (1) , 533-535
Bi-sensory stimulation as a treatment option for somatic tinnitus
- 7 October 2023
- Published by Springer Nature in European Archives of Oto-Rhino-Laryngology
- Vol. 281 (1) , 533-535
Bi-sensory stimulation as a treatment option for somatic tinnitus
- 26 September 2023
- Published by Elsevier in Asian Journal of Psychiatry
- Vol. 89, 103791
Battered by Cyclone Mocha and the civil war: The ignored mental health of the Burmese
- 26 September 2023
- Published by Elsevier in Asian Journal of Psychiatry
- Vol. 89, 103791
Battered by Cyclone Mocha and the civil war: The ignored mental health of the Burmese
- 4 September 2023
- Published by Springer Nature in Irish Journal of Medical Science (1971 -)
- Vol. 193 (2) , 831-832
Potential of near-infrared spectroscopy (NIRS) as a non-invasive diagnostic tool to contain a global outbreak of malaria
- 4 September 2023
- Published by Springer Nature in Irish Journal of Medical Science (1971 -)
- Vol. 193 (2) , 831-832
Potential of near-infrared spectroscopy (NIRS) as a non-invasive diagnostic tool to contain a global outbreak of malaria
- Open Access
- 16 August 2023
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 85 (10) , 4909-4912
Briumvi: a breakthrough in the treatment of relapsing multiple sclerosis: a review
Multiple sclerosis (MS) is a chronic systemic autoimmune disorder characterized by plaques of demyelination, autoimmune inflammation, and astrocytic gliosis. The primary cells involved in the pathophysiology of MS are T cells. However, B cells have recently been implicated in the pathophysiology of the disease. Therefore, researchers have been exploring B cell therapy as an alternative treatment option for MS. B cell therapy is based on the targeted depletion of CD20-positive B cells. Rituximab, ocrelizumab, and ofatumumab are anti-CD20 antibodies already approved. Briumvi, the fourth type of anti-CD20 antibody was approved by FDA in December 2022, for the treatment of relapsing types of MS, including relapsing-remitting multiple sclerosis, active secondary progressive multiple sclerosis, and clinically isolated syndromes after the drug was tested in two randomized, double-blind, phase III, ULTIMATE I, and II trials which compared Briumvi (ublituximab) with Aubiago (teriflunomide). Ublituximab was found to have a much lower annual relapse rate in the ULTIMATE II trials than teriflunomide. Briumvi is a chimeric recombinant IgG1 monoclonal antibody directed against human CD20 with potential antineoplastic activity. Its mechanism of action involves several distinct processes that collectively lead to the depletion of B cells and suppression of the immune response. The primary mode of action of Briumvi is its high-affinity binding to CD20. Infusion-related reactions are the most common side effects encountered following intravenous administration of ublituximab.
- 16 August 2023
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 85 (10) , 4909-4912
Open AccessBriumvi: a breakthrough in the treatment of relapsing multiple sclerosis: a review
Multiple sclerosis (MS) is a chronic systemic autoimmune disorder characterized by plaques of demyelination, autoimmune inflammation, and astrocytic gliosis. The primary cells involved in the pathophysiology of MS are T cells. However, B cells have recently been implicated in the pathophysiology of the disease. Therefore, researchers have been exploring B cell therapy as an alternative treatment option for MS. B cell therapy is based on the targeted depletion of CD20-positive B cells. Rituximab, ocrelizumab, and ofatumumab are anti-CD20 antibodies already approved. Briumvi, the fourth type of anti-CD20 antibody was approved by FDA in December 2022, for the treatment of relapsing types of MS, including relapsing-remitting multiple sclerosis, active secondary progressive multiple sclerosis, and clinically isolated syndromes after the drug was tested in two randomized, double-blind, phase III, ULTIMATE I, and II trials which compared Briumvi (ublituximab) with Aubiago (teriflunomide). Ublituximab was found to have a much lower annual relapse rate in the ULTIMATE II trials than teriflunomide. Briumvi is a chimeric recombinant IgG1 monoclonal antibody directed against human CD20 with potential antineoplastic activity. Its mechanism of action involves several distinct processes that collectively lead to the depletion of B cells and suppression of the immune response. The primary mode of action of Briumvi is its high-affinity binding to CD20. Infusion-related reactions are the most common side effects encountered following intravenous administration of ublituximab.
- 7 August 2023
- Published by Springer Nature in Archives of Women's Mental Health
- Vol. 26 (5) , 717-718
Mental health issues following sexual assault among the flood-affected women of Pakistan
- 7 August 2023
- Published by Springer Nature in Archives of Women's Mental Health
- Vol. 26 (5) , 717-718
Mental health issues following sexual assault among the flood-affected women of Pakistan
- 24 May 2023
- Published by Taylor & Francis in Medicine, Conflict and Survival
- Vol. 39 (3) , 250-257
A rising threat of urinary tract infections among the flood-affected women of Pakistan: challenges and recommendations
- 24 May 2023
- Published by Taylor & Francis in Medicine, Conflict and Survival
- Vol. 39 (3) , 250-257
A rising threat of urinary tract infections among the flood-affected women of Pakistan: challenges and recommendations